Total words: 3090 | 2-word phrases: 781 | 3-word phrases: 884 | 4-word phrases: 960
PAGE INFO
| Title | Try to keep the title under 60 characters (59 characters)
Biotech Insider – Insider News From The Biotech World |
| Description | Try to keep the meta description between 50 - 160 characters (0 characters)
|
| Keywords | Meta keywords are not recommended anymore (0 characters)
|
| H1 | No H1 tag on the page (0 characters)
|
ONE WORD PHRASES 465 Words
| # |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
| 1 | for | | | | | | | 38 | 8.17% |
| 2 | news | | | | | | | 34 | 7.31% |
| 3 | to | | | | | | | 29 | 6.24% |
| 4 | by | | | | | | | 28 | 6.02% |
| 5 | a | | | | | | | 27 | 5.81% |
| 6 | team | | | | | | | 27 | 5.81% |
| 7 | the | | | | | | | 26 | 5.59% |
| 8 | june | | | | | | | 24 | 5.16% |
| 9 | 2024 | | | | | | | 24 | 5.16% |
| 10 | in | | | | | | | 19 | 4.09% |
TWO WORD PHRASES 781 Words
| # |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
| 1 | by news | | | | | | | 24 | 3.07% |
| 2 | news team | | | | | | | 20 | 2.56% |
| 3 | 2024 by | | | | | | | 19 | 2.43% |
| 4 | june 28 | | | | | | | 16 | 2.05% |
| 5 | 28 2024 | | | | | | | 14 | 1.79% |
| 6 | phase 2 | | | | | | | 14 | 1.79% |
| 7 | a phase | | | | | | | 10 | 1.28% |
| 8 | me too | | | | | | | 10 | 1.28% |
| 9 | to a | | | | | | | 9 | 1.15% |
| 10 | review – | | | | | | | 7 | 0.90% |
| 11 | market review | | | | | | | 7 | 0.90% |
| 12 | june 29 | | | | | | | 7 | 0.90% |
| 13 | 29 2024 | | | | | | | 7 | 0.90% |
| 14 | – june | | | | | | | 6 | 0.77% |
| 15 | crunching 70k | | | | | | | 5 | 0.64% |
| 16 | syndrome too | | | | | | | 5 | 0.64% |
| 17 | case for | | | | | | | 5 | 0.64% |
| 18 | the case | | | | | | | 5 | 0.64% |
| 19 | loudly for | | | | | | | 5 | 0.64% |
| 20 | pharma rd | | | | | | | 5 | 0.64% |
THREE WORD PHRASES 884 Words
| # |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
| 1 | by news team | | | | | | | 19 | 2.15% |
| 2 | 2024 by news | | | | | | | 18 | 2.04% |
| 3 | 28 2024 by | | | | | | | 14 | 1.58% |
| 4 | june 28 2024 | | | | | | | 14 | 1.58% |
| 5 | a phase 2 | | | | | | | 10 | 1.13% |
| 6 | june 29 2024 | | | | | | | 7 | 0.79% |
| 7 | market review – | | | | | | | 7 | 0.79% |
| 8 | review – june | | | | | | | 6 | 0.68% |
| 9 | – june 29 | | | | | | | 6 | 0.68% |
| 10 | too with phase | | | | | | | 5 | 0.57% |
| 11 | but a phase | | | | | | | 5 | 0.57% |
| 12 | quiet but a | | | | | | | 5 | 0.57% |
| 13 | me too with | | | | | | | 5 | 0.57% |
| 14 | says me too | | | | | | | 5 | 0.57% |
| 15 | speaks loudly for | | | | | | | 5 | 0.57% |
| 16 | collab to go | | | | | | | 5 | 0.57% |
| 17 | loudly for the | | | | | | | 5 | 0.57% |
| 18 | win speaks loudly | | | | | | | 5 | 0.57% |
| 19 | aiderived psychedelic on | | | | | | | 5 | 0.57% |
| 20 | due for fda | | | | | | | 5 | 0.57% |
| 21 | silence collab to | | | | | | | 5 | 0.57% |
| 22 | mallinckrodt silence collab | | | | | | | 5 | 0.57% |
| 23 | crinetics nears fda | | | | | | | 5 | 0.57% |
| 24 | looks to test | | | | | | | 5 | 0.57% |
| 25 | growth disease drug | | | | | | | 5 | 0.57% |
| 26 | disease drug a | | | | | | | 5 | 0.57% |
| 27 | drug a phase | | | | | | | 5 | 0.57% |
| 28 | crunching 70k ‘trip | | | | | | | 5 | 0.57% |
| 29 | the case for | | | | | | | 5 | 0.57% |
| 30 | for fda nod | | | | | | | 5 | 0.57% |
FOUR WORD PHRASES 960 Words
| # |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
| 1 | 2024 by news team | | | | | | | 15 | 1.56% |
| 2 | june 28 2024 by | | | | | | | 14 | 1.46% |
| 3 | 28 2024 by news | | | | | | | 13 | 1.35% |
| 4 | market review – june | | | | | | | 6 | 0.63% |
| 5 | review – june 29 | | | | | | | 6 | 0.63% |
| 6 | – june 29 2024 | | | | | | | 6 | 0.63% |
| 7 | growth disease drug a | | | | | | | 5 | 0.52% |
| 8 | for fda nod ionis | | | | | | | 5 | 0.52% |
| 9 | due for fda nod | | | | | | | 5 | 0.52% |
| 10 | drug due for fda | | | | | | | 5 | 0.52% |
| 11 | mash drug due for | | | | | | | 5 | 0.52% |
| 12 | first mash drug due | | | | | | | 5 | 0.52% |
| 13 | mallinckrodt silence collab to | | | | | | | 5 | 0.52% |
| 14 | silence collab to go | | | | | | | 5 | 0.52% |
| 15 | quiet but a phase | | | | | | | 5 | 0.52% |
| 16 | says me too with | | | | | | | 5 | 0.52% |
| 17 | but a phase 2 | | | | | | | 5 | 0.52% |
| 18 | weekly market review – | | | | | | | 5 | 0.52% |
| 19 | win speaks loudly for | | | | | | | 5 | 0.52% |
| 20 | disease drug a phase | | | | | | | 5 | 0.52% |
| 21 | drug a phase 2 | | | | | | | 5 | 0.52% |
| 22 | home 20mplus payday in | | | | | | | 5 | 0.52% |
| 23 | me too with phase | | | | | | | 5 | 0.52% |
| 24 | speaks loudly for the | | | | | | | 5 | 0.52% |
| 25 | mortgage rates put off | | | | | | | 4 | 0.42% |
| 26 | rates put off many | | | | | | | 4 | 0.42% |
| 27 | team all posts in | | | | | | | 4 | 0.42% |
| 28 | after crunching 70k ‘trip | | | | | | | 4 | 0.42% |
| 29 | crunching 70k ‘trip reports’ | | | | | | | 4 | 0.42% |
| 30 | news team all posts | | | | | | | 4 | 0.42% |
| 31 | a phase 2 test | | | | | | | 4 | 0.42% |
| 32 | makes the case for | | | | | | | 4 | 0.42% |
| 33 | the case for carcinoid | | | | | | | 4 | 0.42% |
| 34 | sanofi shutting down rd | | | | | | | 4 | 0.42% |
| 35 | jj’s john reed takes | | | | | | | 4 | 0.42% |
| 36 | shutting down rd site | | | | | | | 4 | 0.42% |
| 37 | a phase 2 cardiovascular | | | | | | | 4 | 0.42% |
| 38 | takes home 20mplus payday | | | | | | | 4 | 0.42% |
| 39 | put off many home | | | | | | | 4 | 0.42% |
| 40 | 20mplus payday in his | | | | | | | 4 | 0.42% |
EXTERNAL LINKS